Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04579926 · ClinicalTrials.gov registry record · NA

PINPOINT: Gaming Technology for SCD Pain

A NA study, sponsored by Klein Buendel.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT04579926 is a NA study that has completed, run by Klein Buendel. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04579926, a NA study, has completed, sponsored by Klein Buendel.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet programs to assist SCD adolescents with better identification and communication about pain are lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve self-care. Pinpoint is an interactive gaming app that will be tested in a Phase II project to determine whether the app assists SCD teens with improving their communication and identification skills for pain self-report.

Interventions

  • OTHER Pinpoint app

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2018-09-19
Est. Completion 2022-06-30
Phase NA

Sponsor

Klein Buendel

34 total trials

What the Registry Record Tells You About NCT04579926

The ClinicalTrials.gov registry entry for NCT04579926 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Klein Buendel, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Pinpoint app is the first listed.

NCT04579926 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04579926 about?

NCT04579926 is a clinical study titled "PINPOINT: Gaming Technology for SCD Pain". Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet programs to assist SCD adolescents with better identification and communication about pain are lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especi...

What is the current status of trial NCT04579926?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2018-09-19. Estimated completion is 2022-06-30.

What interventions are being tested in trial NCT04579926?

The interventions under investigation include: Pinpoint app (OTHER).

Who is sponsoring clinical trial NCT04579926?

This trial is sponsored by Klein Buendel, which has 34 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.